From the University of Bristol, England
Joint replacement has alleviated the suffering of millions of patients who would otherwise be crippled by arthritis. Whatever the uncertainties about the effects of this procedure, the benefits are very real. This is of paramount importance when evaluating any risks from surgery. Uncertainties arise because all foreign materials produce a tissue reaction when they are implanted in the body. The swelling caused by a thorn is a typical example. Orthopaedic materials are not exempt from a reaction by the host. This becomes most pronounced when wear of a replacement arthroplasty generates huge numbers of particles of metal, cement (polymethylmethacrylate and additives) and polyethylene as well as soluble metal. These particles provoke an inflammatory reaction, which in turn contributes to local tissue destruction and aseptic loosening. The particles are also disseminated systemically in the body at lower concentrations to local and distant lymph nodes, the liver and the spleen. 1 The soluble metal is released into the circulation and excreted in the urine. 2 Since wear debris can elicit a local reaction is it possible that its systemic dissemination could induce a systemic effect, especially in the long term? A systemic effect caused by lower concentrations of particles may take time to become manifest. This was therefore not a relevant issue in the past, since Sir John Charnley initially insisted that joint replacement surgery be restricted to the elderly. However, because of its success, increasingly younger patients have been treated. Approximately one-third of those now undergoing joint replacement are less than 60 years old 3 and a tenth are under 40. A minority of patients may therefore be exposed to orthopaedic materials for up to 60 years. The wear debris includes metals such as chromium, nickel, cobalt, aluminium, titanium and vanadium which may have allergic, toxic and mutagenic effects in other situations. There is therefore concern that there may be long-term risks associated with joint replacement either to the patient or, in theory, to any children which they may conceive. In industry the exposure of workers or the environment to the same metals is regulated by biomonitoring 4 and by law, 5 respectively.
In orthopaedic surgery the priority for the treatment of a young patient is the use of a prosthesis which is associated with the least amount of aseptic loosening, at least in the short term. There has, however, been a plethora of new joint replacements of many designs. These are likely to have different rates of wear, both in terms of volume and in the numbers of particles of different size and shape which are produced, either of which may determine the long-term biological response to the wear debris. 6, 7 In particular, it seems reasonable to assume that porous-coated implants of pure titanium, titanium-alloy or cobalt-chrome, and those in which cobalt-chrome articulates with cobalt-chrome, may provoke higher rates of soluble and finely particulate debris. Porous-coated implants may release more metal simply because there is a much larger surface area exposed to the patient: they are not cemented and the surface is highly convoluted. The cobalt-chrome/cobalt-chrome bearings release more metal because of abrasive wear. Cementless implants and those with joint surfaces which are thought to last longer are used particularly in young adults. Thus a patient who will be exposed to metal release for longer than average, may receive an implant with higher than average rates of release. So far, clinical follow-up has been short compared with the lifetime of the patient, and the long-term effects are therefore unknown. A study of revision of a metal-on-plastic hip replacements showed a twofold increase in asymmetrical chromosomal aberrations in the cells of the bone marrow adjacent to the prosthesis.
operation, but in two out of 21 patients at the longest postoperative interval there was a clonal expansion of lymphocytes in the bone marrow and peripheral blood. There were large amounts of metal in the bone marrow compared with that of control patients, with chromium increased by ϫ 6700, cobalt by ϫ 850 and metal by ϫ 580 in paired samples. There was also an increase in symmetrical aberrations in the peripheral blood of patients undergoing such revision. 9 This consisted of chromosome translocations, in which one segment of a chromatid is exchanged with another and of aneuploidy involving, in this case, a gain of a chromosome. These aberrations are usually not lethal and are cumulative. Two observations point to an influence from the metals. The first is that the type of chromosomal aberration seen in vivo depends on the composition of the metal alloy. Patients with titanium-vanadium-aluminium-alloy prostheses showed a fivefold increase in aneuploidy with no rise in chromosome translocations, while those with cobaltchrome prostheses showed a 2.5-fold increase in aneuploidy and a 3.5-fold rise in chromosome translocations. The second is that this differential response was confirmed in vitro, when human cells in tissue culture were exposed to titanium-alloy-or cobalt-chrome-alloy-based wear debris which had been extracted from the periprosthetic tissues of patients at revision arthroplasty. 10 One of the hallmarks of malignancy is an increase in chromosome translocations and aneuploidy. Some chromosome translocations are pathognomonic of certain types of lymphoma, for example, t14:18 in follicular lymphoma. If cancer therefore implies an increase in chromosomal aberrations does the reverse hold true? Unfortunately, we do not have enough data to be able to answer this question reliably.
In molecular epidemiology, DNA adducts, DNA damage and chromosomal aberrations and mutations have all been investigated for their links with the development of cancer. 11 These markers have been used to investigate the aetiology of disease, to monitor individuals at risk, to investigate methods for protection against disease and to assess individual susceptibility to causative agents. This approach is still at an early stage and observations thus far have exposed its limitations rather than its success. Prospective studies are necessary to assess the predictive value of a biomarker. Chromosomal aberrations are probably the only marker which has proved valuable in a limited number of studies. In two, carried out in Scandinavia and Italy, the level of chromosomal aberrations in peripheral blood lymphocytes was measured at the start of the study and the development of cancer was subsequently monitored over several decades. Patients whose levels of aberration fell into the top third of the sample had a twofold greater incidence of malignancy, with a particular increase in lung cancer and especially in lymphoma, compared with those with levels in the bottom third. The interpretation of this information, however, is complex since the risk for high versus low levels of chromosomal aberrations was similar in subjects who were heavily exposed to environmental carcinogens and in those who had never been exposed to any major carcinogenic agent during their lifetime, suggesting that chromosomal damage itself is somehow involved in the pathway to cancer.
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The International Agency for Research into Cancer (IARC) has recently reviewed the epidemiological data for the risk of malignancy after joint replacement 13 in 14 cohort studies of patients with total hip or knee replacements in six countries. Four studies revealed an excess of cancers at specific sites including Hodgkin's disease, nonHodgkin's lymphoma, leukaemia and renal carcinoma. The IARC noted that most studies did not provide information on possible confounding variables such as immunosuppressive therapy or rheumatoid arthritis. In most, the follow-up was considered to be too short to investigate cancer many years after exposure. They also noted that the mutagenicity and carcinogenicity of biomaterials are influenced by the exact composition of the biomaterial, its surface properties, the composition and rate of release of leachable materials, the physical environment and degradation, which may lead to the formation of compounds with different mutagenic properties. Much of the information for assessment was considered to be inadequate. They therefore placed orthopaedic implants under group 3, i.e., not classifiable. It is notable that epidemiological studies have compared orthopaedic patients with the general population, which is not ideal because of the problems caused by confounding variables. For example, certain cancers, such as carcinoma of the lung, were consistently decreased, which may well reflect a smaller number of smokers in the orthopaedic population.
It is of course easy to ask whether there are long-term risks after joint replacement. In order to attempt to answer this a large amount of data is required. In the immediate and short term there is a need for an epidemiological analysis which includes an internal comparison between orthopaedic patients. Is there a relative risk for patients with metal-on-metal implants compared with metal-onplastic and ceramic prostheses? Is there a difference between patients with titanium-alloy, cobalt-chrome-alloy and stainless-steel implants? In the long term a prospective study would need to be initiated in which the analysis was not restricted to cancer but included toxicity and hypersensitivity, as well as an analysis of fetal damage either by maternal exposure in utero or paternal risk before conception.
14 Such a study would be more powerful if it included the measurement of biological parameters and metal levels and allowed comparison with other molecular epidemiological studies. A system of prospective biomonitoring would also establish whether there are thresholds for exposure which are of concern. Such an investigation may provoke unnecessary concern and patient anxiety about well-established techniques, but without it there will be no knowledge with which to combat spurious changes of practice and litigation. It is most important to maintain a clear perspective. Our knowledge is lacking. The surgeon does have a choice between different materials to implant in a young patient, but there is no clear indication as to which is the most biocompatible in the long term. We are left with uncertainties while "we demand guaranteed and rigidly defined areas of doubt and uncertainty". 15 The reality is that joint replacement surgery has revolutionised the treatment of arthritis and will continue to be effective in the alleviation of suffering. The longer-term biological implications of wear debris need to be judged against the proven record of clinical success.
